Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shannon Leah Schmidt"'
Autor:
Douglas B. Evans, Beth Erickson, Shannon Leah Schmidt, James P. Thomas, Paul S. Ritch, Vipal Durkal, Kathleen K. Christians, Ben George, Shinoj Pattali Jayavalsan, Susan Tsai
Publikováno v:
Journal of Clinical Oncology. 34:428-428
428 Background: FOLFIRINOX(FFX)/FOLFOX(FX) and Nab-paclitaxel plus Gemcitabine (NabG) represent standard first line (FL) treatment options for MPAC, but there is no prospective data to ascertain the ideal sequence of these regimens when used off prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4eaf834da40683e85d90cbcf2854512e
https://doi.org/10.1200/jco.2016.34.4_suppl.428
https://doi.org/10.1200/jco.2016.34.4_suppl.428
Autor:
Douglas B. Evans, Ben George, James P. Thomas, Vipal Durkal, Paul S. Ritch, Susan Tsai, Beth Erickson, Shannon Leah Schmidt, Kathleen K. Christians, Shinoj Pattali Jayavalsan
Publikováno v:
Journal of Clinical Oncology. 34:397-397
397 Background: Standard front line (FL) chemotherapy regimens for MPAC include FOLFIRINOX (FFX)/FOLFOX(FX) and Nab-paclitaxel plus Gemcitabine (NabG). Outcome data in patients treated with both FFX/FX and NabG has not been well characterized. We ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d99eca3d7a4cae07f9cf883a2a89d5d
https://doi.org/10.1200/jco.2016.34.4_suppl.397
https://doi.org/10.1200/jco.2016.34.4_suppl.397
Autor:
Ben George, Shannon Leah Schmidt, Vipal Durkal, Susan Tsai, Paul S. Ritch, Douglas B. Evans, Kathleen K. Christians, Shinoj Pattali Jayavalsan, Beth Erickson, James P. Thomas
Publikováno v:
Journal of Clinical Oncology. 34:443-443
443 Background: Front-line (FL) chemotherapy regimens for MPAC include FOLFIRINOX (FFX)/FOLFOX (FX) and Nab-paclitaxel plus Gemcitabine (NabG). We examined our hypothesis that objective response (OR) to these regimens can influence clinical outcome w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20b6d67ce178d3a691c9bfc2eceb7dac
https://doi.org/10.1200/jco.2016.34.4_suppl.443
https://doi.org/10.1200/jco.2016.34.4_suppl.443
Autor:
Shannon Leah Schmidt, Paul E. Knudson, Mei-Jie Zhang, Timothy S. Fenske, Daniel Eastwood, Emily L. Richter, Linda S. Blust, Jeanne Palmer, Ehab Atallah
Publikováno v:
Blood. 120:4323-4323
Abstract 4323 Introduction: Hyperglycemia (HyG) has been shown to be detrimental in acute leukemia. In patients with acute myelogenous leukemia, hyG was associated with increased hospital mortality (Ali, et. al. Cancer 2007) while in patients with ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60062920c88cc8e3ea55c51d6f476b67
https://doi.org/10.1182/blood.v120.21.4323.4323
https://doi.org/10.1182/blood.v120.21.4323.4323